Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck

Head and Neck

Volumn 35, Issue 3, 2013, Pages 443-453

  Shin, Dong M ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cetuximab; EGFR; panitumumab; recurrent metastatic SCCHN

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; IFOSFAMIDE; LAPATINIB; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLATINUM; RO 5083945; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ACUTE KIDNEY FAILURE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COPY NUMBER VARIATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART MUSCLE ISCHEMIA; HUMAN; HYPOMAGNESEMIA; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; REPEAT PROCEDURE; REVIEW; SALVAGE THERAPY; SEPSIS; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84874107117     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21910     Document Type: Review

References (73)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
3. D'souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
4. Gillison ML, D'souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers. Vol. 2. 2008. May be accessed at www.nccn.org
6. Langer CJ,. Targeted therapy in head and neck cancer. State of the art 2007 and review of clinical applications. Cancer 2008; 112: 2635-2645.
7. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518-5523.
8. Lee SC, Shores CG, Weissler MC,. Salvage surgery after failed primary concomitant chemoradiation. Curr Opin Otolaryngol Head Neck Surg 2008; 16: 135-140.
9. Pathak I, Gilbert R, Davidson J, Brit D,. Efficacy of surgical salvage for advanced neck metastases after radiotherapy failure. J Otolaryngol 2000; 29: 340-343.
10. Richey LM, Shores CG, George J, et al. The effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancer. Otolaryngol Head Neck Surg 2007; 136: 98-103.
11. Gleich LL, Ryzenman J, Gluckman JL, Wilson KM, Barrett WL, Redmond KP,. Recurrent advanced (T3 or T4) head and neck squamous cell carcinoma. Is salvage possible? Arch Otolaryngol Head Neck Surg 2004; 130: 35-38.
12. Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope 2007; 117: 1019-1023.
13. Lee N, Chan K, Bekelman JE, et al. Salvage reirradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68: 731-740.
14. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009; 73: 399-409.
15. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263.
16. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
17. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA,. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
18. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
19. Vermorken JB,. Panitumumab with cisplatin and 5-FU as 1st-line treatment of recurrent or metastatic SCCHN: the phase 3 SPECTRUM study. Ann Oncol (ESMO) 2010; 21: Abstract LBA26.
20. Urba SG,. Pemetrexed in combination with cisplatin versus cisplatin plus placebo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a randomized phase III study. Ann Oncol (ESMO) 2010; 21:Abstract 1003O.
21. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
22. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832.
23. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170.
24. Li S, Schmitz KR, Jeffrey PD, Wiltzius PD, Kussie P, Ferguson KM,. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-311.
25. Taylor RJ, Chan SL, Wood A, et al. FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009; 58: 997-1006.
26. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
27. Ang KK, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011; 29 (Suppl 15s):Abstract 5500.
28. Mesia R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21: 1967-1973.
29. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL,. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22: 77-85.
30. Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
31. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27: 2009; 1864-1871.
32. Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A,. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27 (Suppl 303s):Abstract 6011.
33. Del Campo JM, Sebastian P, Hitt R, et al. Effect of lapatinib monotherapy on apoptosis and proliferation: results of a phase II randomised study in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ESMO 2008:Abstract 6880.
34. Specenier PM, Lalami Y, Vermorken J, et al. EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). J Clin Oncol 2009; 27 (Suppl 15s):Abstract 6017.
35. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006; 24 (Suppl 18S):Abstract 5568.
36. Patel D, Guo X, Ng S, et al. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010; 19: 89-99.
37. Markman B, Gomez-Roca C, Cervantes-Ruiperez A, et al. Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC). J Clin Oncol 2010; 28 (Suppl 15s):Abstract 2522.
38. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-5101.
39. Argiris A, Kotsakis AP, Kim S, et al. Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): final results. J Clin Oncol 2011; 29 (Suppl 15s):Abstract 5564.
40. Cohen EEW, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-257.
41. Babu KG, Viswanath L, Reddy BK, et al. An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study. J Clin Oncol 2010; 28 (Suppl 15s):Abstract 5530.
42. Gupta M, Madholia V, Gupta N, et al. Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck. J Clin Oncol 2010; 28 (Suppl 15s):Abstract 5565.
43. León X, Hitt R, Constenla M, et al. A retrospective analysis of outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to platinum-based chemotherapy. Clin Oncol 2005; 17: 418-424.
44. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
45. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
46. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587.
47. Seiwert T, Fayette J, DelCampo JM, et al. A randomized, open-label phase II study of afatinib (BIBW 2992) versus cetuximab in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC) after failure of platinum-containing therapy with a cross-over period for progressing patients. Ann Oncol (ESMO) 2010; 21:Abstract 1010PD.
48. Machiels J-P, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011; 12: 333-343.
49. Saura C, Baselga J, Herbst R, et al. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study. J Clin Oncol 2009; 27 (Suppl 15s):Abstract 6023.
50. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28: 3330-3335.
51. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-3773.
52. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
53. Rocco JW, Sidransky D,. P16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42-55.
54. Rischin D, Young R, Fisher R, et al. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. J Clin Oncol 2009; 27 (Suppl 302s):Abstract 6004.
55. Licitra L, Rolland F, Bokemeyer C, et al. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol 2009; 27 (Suppl 302s):Abstract 6005.
56. Amin AR, Thakur VS, Gupta K, et al. Restoration of p53 functions protects cells from concanavalin A-induced apoptosis. Mol Cancer Ther 2010; 9: 471-479.
57. Lippman SM, Shin DM, Lee JJ, et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995; 55: 16-19.
58. Shin DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 519-529.
59. Clayman GL, Frank DK, Bruso PA, Goepfert H,. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999; 7: 1715-1722.
60. Nemunaitis J, Clayman G, Agarwala SS, et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 2009; 15: 7719-7725.
61. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
62. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 2000; 18: 609-622.
63. Nemunaitis J, Ganly I, Khuri FR, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: phase II trial. Cancer Res 2000; 60: 6359-6366.
64. Mita A, Sankhala K, Sarantopalos J, et al. A phase II study of intravenous (IV) Reolysin (wild type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. Poster presented at the 15th Annual Connective Tissue Oncology Society Meeting; November 5-9, 2009; Miami, FL.
65. Karapanagiotou E, Pandha H, Hall G, et al. Phase I/II trial of oncolytic reovirus (REOLYSIN®) in combination with carboplatin/paclitaxel in patients with advanced solid cancers. Poster presented at the International Society for Biological Therapy of Cancer; 2008; San Diego, CA.
66. Harrington KJ, Karapanagiotou E, Hardev P, et al. Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN). Poster presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference; 2009; Boston, MA. Mol Cancer Ther 2009;8(12 Suppl):B242.
67. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 893-891.
68. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754.
69. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-bas concurrent chemoradiation. Br J Cancer 2008; 99: 197-172.
70. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated with cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 3855-3859.
71. Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 66: 1022-1030.
72. Chung C, Seely EH, Grigorieva J, et al. Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. J Clin Oncol 2009; 27 (Suppl 15s):Abstract 6000.
73. Saba NF, Wang X, Müller S, et al. Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head Neck 2009; 31: 475-481.